A Brisbane研制的药物在180名病人中扭转了与败血症有关的器官损伤,目前正在进行最后临床试验。 A Brisbane-developed drug reversed sepsis-related organ damage in 180 patients and is now in final clinical trials.

A Brisbane研制的药物在治疗败血症方面很有希望,败血症是一种致命疾病,造成全球五分之一的死亡,目前没有治疗方法。 A Brisbane-developed drug shows promise in treating sepsis, a deadly condition causing about one in five global deaths, with no current cure. 该药物由格里菲斯大学研究人员研发，香港大药集团进行测试，通过靶向败血症释放的关键分子，逆转了180名中国患者的器官损伤。 Created by Griffith University researchers and tested by Hong Kong’s Grand Pharmaceutical Group, the drug reversed organ damage in 180 Chinese patients by targeting a key molecule released during sepsis. 它已经进入了第3阶段临床试验,这是可能获得批准之前的最后阶段,标志着在应对这一重大全球健康威胁方面可能取得突破。 It has advanced to stage-three clinical trials, the final phase before potential approval, marking a potential breakthrough in combating this major global health threat.